- Home
- FFA vs ATAI Comparison
FFA vs ATAI Comparison
Compare FFA & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- ATAI
- Stock Information
- Founded
- FFA 2004
- ATAI 2018
- Country
- FFA United States
- ATAI Germany
- Employees
- FFA N/A
- ATAI N/A
- Industry
- FFA Investment Managers
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- FFA Finance
- ATAI Health Care
- Exchange
- FFA Nasdaq
- ATAI Nasdaq
- Market Cap
- FFA 414.0M
- ATAI 444.7M
- IPO Year
- FFA N/A
- ATAI 2021
- Fundamental
- Price
- FFA N/A
- ATAI $3.49
- Analyst Decision
- FFA
- ATAI Strong Buy
- Analyst Count
- FFA 0
- ATAI 2
- Target Price
- FFA N/A
- ATAI $10.50
- AVG Volume (30 Days)
- FFA 26.1K
- ATAI 8.6M
- Earning Date
- FFA 01-01-0001
- ATAI 08-12-2025
- Dividend Yield
- FFA 6.72%
- ATAI N/A
- EPS Growth
- FFA N/A
- ATAI N/A
- EPS
- FFA N/A
- ATAI N/A
- Revenue
- FFA N/A
- ATAI $1,863,000.00
- Revenue This Year
- FFA N/A
- ATAI $423.05
- Revenue Next Year
- FFA N/A
- ATAI N/A
- P/E Ratio
- FFA N/A
- ATAI N/A
- Revenue Growth
- FFA N/A
- ATAI 572.56
- 52 Week Low
- FFA $15.84
- ATAI $1.03
- 52 Week High
- FFA $19.30
- ATAI $4.00
- Technical
- Relative Strength Index (RSI)
- FFA 66.70
- ATAI 63.92
- Support Level
- FFA $20.69
- ATAI $3.06
- Resistance Level
- FFA $20.94
- ATAI $4.00
- Average True Range (ATR)
- FFA 0.16
- ATAI 0.26
- MACD
- FFA -0.01
- ATAI 0.04
- Stochastic Oscillator
- FFA 65.24
- ATAI 64.97
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.